prof. RNDr. Ondřej Slabý, Ph.D.
Research Group Leader Senior, Ondřej Slabý Research Group
Office: bldg. B06/209
Kamenice 753/5
625 00 Brno
Phone: | +420 549 49 6876 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 686
2019
-
Role určení molekulární podskupiny ependymomu v predikci prognózy – příklady konkrétních pacientů
Year: 2019, type: Conference abstract
-
Sarcoma Stem Cell Heterogeneity
STEM CELLS HETEROGENEITY - NOVEL CONCEPTS, year: 2019, volume: 1123, edition: 2019, DOI
-
Sekvenování krátkých RNA a validace vybraných MikroRNA v mozkomíšním moku u pacientů s mozkovými nádory
Year: 2019, type: Conference abstract
-
Současné možnosti radioterapie mozkových metastáz solidních nádorů
Onkologie, year: 2019, volume: 13, edition: 4, DOI
-
Současný pohled na HPV asociované karcinomy orofaryngu a roli p16 jako surogátního markeru high-risk HPV
Klinická onkologie, year: 2019, volume: 32, edition: 4, DOI
-
Syndrom DICER1
Klinická onkologie, year: 2019, volume: 32, edition: Supplementum 2, DOI
-
Testing of library preparation methods for transcriptome sequencing of real life glioblastoma and brain tissue specimens: A comparative study with special focus on long non-coding RNAs
Plos one, year: 2019, volume: 14, edition: 2, DOI
-
Translational Potential of MicroRNAs for Preoperative Staging and Prediction of Chemoradiotherapy Response in Rectal Cancer
Cancers, year: 2019, volume: 11, edition: 10, DOI
-
Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, year: 2019, volume: 37, edition: 3, DOI
-
Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, year: 2019, volume: 37, edition: 4, DOI